🔗 Share this article

A shadow economy for unlicensed slimming medications is being driven by TikTok fitness influencers and sellers on messaging platforms, based on recent findings.

Investigational Treatment Gaining Traction Online

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Separately, a robust trade exists on messaging services, where communities with thousands of members share “before and after” photos, administration instructions and claims of next-day British shipping. Sellers promote the drug there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic.

Healthcare Professionals Express Worries

Nevertheless, physicians and pharmacists have cautions that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could lead to individuals administering substances of unknown origin.

Some professionals said the popularity for retatrutide could be connected to the rising price of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Selling retatrutide on social media or Telegram is prohibited in the UK, as it is an unapproved drug that cannot be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still violate pharmaceutical, marketing, and customer regulations, risking fines, legal action or prison.

Service Reaction and Content Removal

According to the social media company, the service has taken down violative content and banned associated hashtags and search suggestions. The organization stated it was committed to maintaining the service secure and investing in strengthening enforcement strategies.

Online Trading Activities

Research also discovered groups with up to 9,000 participants selling the experimental drug using the platform's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” instantly brings up channels with thousands of users, filled with images of slimming results, glowing reviews and detailed instructions for preparing or administering at home.

Within moments of joining one community, a vendor posted contact information, where the majority of purchases occur. The vendor provided an instruction manual and guaranteed delivery within 48 hours. When asked whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. None inquired about body mass, medical conditions or past usage.

Product Details and Costs

Within these communities, posts show black plastic packages with Royal Mail stickers, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors usually priced at 160 pounds for 20mg. When questioned how much time a pen should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Safety Measures

A spokesperson for the messaging service stated it regularly moderated harmful content on its platform including content that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they can’t verify. Although the research behind this drug is valid, these digital products may not contain what they claim,” said a pharmacy expert, the director of pharmacy at Chemist4U.

A medical professional of Asda Online Doctor connected the surge in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit injections are extremely dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she said.

Her staff has already encountered individuals harmed by personal administration from unconfirmed suppliers. “We recognize the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may expose patients to possibly significant medical dangers”.